LAKEWOOD-AMEDEX BIOTHERAPEUTLABT
ASignal's systematic analysis rates LABT as Bearish.
Reflects the latest available analysis · analyzed Sep 26, 2026
The case on LABT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Low debt-to-equity ratio (0.02x)
- High current and quick ratios (7.70x, 7.29x) indicating liquidity strength
- Positive cash position ($4.58M) relative to market cap
- Negative return on equity (-402.83%) and return on assets (-139.40%)
- Zero profit, operating, and gross margins
- Negative operating and free cash flow
- Declining price momentum and trading below key moving averages (SMA20, SMA50)
- MACD below signal line with negative histogram, indicating downtrend
- No Reddit mentions, suggesting lack of retail interest or visibility
See the full verdict on LABT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes LABT
Most investors never get a second opinion, let alone several. ASignal runs LABT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.